CRBP
NASDAQCorbus Pharmaceuticals Holdings Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$10.09-0.01 (-0.05%)
01:30 PM07:45 PM
News · 26 weeks44-12%
2025-11-022026-04-26
Mix2490d
- SEC Filings12(50%)
- Insider6(25%)
- Other6(25%)
Latest news
25 items- PRCorbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701NORWOOD, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on promising new therapies in oncology and obesity, today announced that updated clinical data from its Phase 1/2 study of CRB-701, a next generation Nectin-4 ADC, in both head and neck squamous cell carcinoma (HNSCC) and cervical cancer will be presented at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2 in Chicago, IL. The data will include clinical response durability as well as HNSCC patient subgroup analysis. Corbus previously presented dose optimization data from the study, including encoura
- SECSEC Form DEFA14A filed by Corbus Pharmaceuticals Holdings Inc.DEFA14A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
- SECCorbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
- SECCorbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
- PRCorbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for ObesityOn track to complete 16-week, dose-finding Phase 1b study (n=240) in summer 2026 Phase 1b data will build upon Phase 1a findings that demonstrated weight loss of nearly 3% at 14 days in individuals with obesity CRB-913 is a non-incretin daily oral small molecule with the potential to deliver a therapeutic option for weight loss and long-term weight management NORWOOD, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on promising new therapies in oncology and obesity, today announced the last patient has been enrolled and completed the first clinical visit (Last Patient First Visit) in the Company's CANYON-1 P
- SECCorbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
- PRCorbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical CancerFDA feedback enables Corbus to proceed with proposed registrational study design and endpoints to support potential accelerated approval in second-line HNSCC and cervical cancer Updated CRB-701 monotherapy data accepted for presentation at ASCO 2026 Dr. Dominic Smethurst to step down as Corbus' Chief Medical Officer on June 30, 2026 NORWOOD, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on promising new therapies in oncology and obesity, today announced broad alignment with the U.S. Food and Drug Administration (FDA) on the registration path for CRB-701, the Company's next-generation, highly stable Nectin-
- SECSEC Form DEFA14A filed by Corbus Pharmaceuticals Holdings Inc.DEFA14A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
- SECSEC Form DEF 14A filed by Corbus Pharmaceuticals Holdings Inc.DEF 14A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
- SECSEC Form 424B3 filed by Corbus Pharmaceuticals Holdings Inc.424B3 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
- SECSEC Form EFFECT filed by Corbus Pharmaceuticals Holdings Inc.EFFECT - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
- PRCorbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health SummitNORWOOD, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused promising new therapies in oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a moderated panel discussion at the BMO 2026 Metabolic Health Summit, to be held in New York, NY, on Tuesday, March 24, 2026. Corbus is advancing CRB-913, an orally delivered highly peripherally restricted CB1 inverse agonist for the treatment of obesity. CRB-913 demonstrated potent, rapid weight loss and favorable GI tolerability in a 14-day Phase 1a SAD/MAD study, suggesting this drug could provide a novel long
- SECSEC Form S-3 filed by Corbus Pharmaceuticals Holdings Inc.S-3 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
- SECSEC Form 10-K filed by Corbus Pharmaceuticals Holdings Inc.10-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
- SECCorbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
- INSIDERChief Medical Officer Smethurst Dominic sold $50,601 worth of shares (6,097 units at $8.30), decreasing direct ownership by 6% to 89,790 units (SEC Form 4)4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
- SECCorbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
- INSIDERChief Operating Officer Hodgson Ian sold $6,253 worth of shares (847 units at $7.38), decreasing direct ownership by 2% to 51,080 units (SEC Form 4)4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
- INSIDERChief Financial Officer Moran Sean F. sold $36,588 worth of shares (4,701 units at $7.78), decreasing direct ownership by 5% to 96,694 units (SEC Form 4)4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
- INSIDERChief Executive Officer Cohen Yuval sold $107,952 worth of shares (13,871 units at $7.78), decreasing direct ownership by 7% to 174,316 units (SEC Form 4)4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
- PRCorbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences ConferenceNORWOOD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present a corporate overview and attend investor meetings at the 36th Annual Oppenheimer Healthcare Life Sciences Conference, to be held virtually February 25-25, 2026. 36th Annual Oppenheimer Healthcare Life Sciences Conference Format: Virtual presentation and one-on-one investor meetings Date: February 25, 2026 Presentation Time: 3:20pm Eastern TimeWebcast Link: Click Here About CorbusCorbus Pharmaceuticals Holdings, Inc. is a clinical stage oncolog
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Corbus Pharmaceuticals Holdings Inc.SCHEDULE 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)
- INSIDERChief Medical Officer Smethurst Dominic sold $26,575 worth of shares (3,285 units at $8.09), decreasing direct ownership by 3% to 95,887 units (SEC Form 4)4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
- INSIDERChief Operating Officer Hodgson Ian sold $19,537 worth of shares (2,415 units at $8.09), decreasing direct ownership by 4% to 51,927 units (SEC Form 4)4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
- INSIDERChief Operating Officer Hodgson Ian was granted 28,365 shares, increasing direct ownership by 109% to 54,342 units (SEC Form 4)4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)